Tumor-initiating cells are not enriched in cisplatin-surviving BRCA1;p53-deficient mammary tumor cells in vivo.
Although many breast cancers respond to chemotherapy or hormonal therapy, lack of tumor eradication is a central clinical problem preceding the development of drug resistant tumors. Using the K14cre;Brca1(F5-13/F5-13);p53(F2-10/F2-10) mouse model for hereditary breast cancer, we have previously studied responses of mammary tumors to clinically relevant anti-cancer drugs, including cisplatin. The BRCA1- and p53-deficient tumors generated in this model are hypersensitive to cisplatin and never become resistant to this agent due to the large, irreversible deletion in Brca1. We show here that even dose-dense treatment with a maximum tolerated dose of cisplatin does not result in complete tumor eradication. To explain this result we have addressed the hypothesis that the lack of eradication of drug-sensitive tumors is due to increased in vivo chemotherapy resistance of tumor-initiating cells (TICs). Using the CD24 and CD49f cell surface markers which detect normal mouse mammary stem cells, we have identified tumor-initiating cells in BRCA1- and p53-deficient tumors. In addition to the Lin⁻/CD24(+)/CD49f(+) subpopulation, we show that a larger population of Lin⁻/CD24(+)/CD49f-cells also has tumor-initiating capability in at least two serial orthotopic transplantations, suggesting that these are not more differentiated transit-amplifying cells. However, we did not find an enrichment of TICs in cisplatin-treated tumor remnants. We conclude that in this model the tolerance of the cisplatin-surviving cells cannot be attributed to special biochemical defense mechanisms of TICs.
Pajic
Marina
M
Division of Molecular Biology of the Netherlands Cancer Institute, Amsterdam, The Netherlands.
Kersbergen
Ariena
A
van Diepen
Frank
F
Pfauth
Anita
A
Jonkers
Jos
J
Borst
Piet
P
Rottenberg
Sven
S
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D051927:CD24 Antigen / Q000378:metabolism; D002945:Cisplatin / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D017353:Gene Deletion; D019398:Genes, BRCA1; D016158:Genes, p53; D039503:Integrin alpha6 / Q000378:metabolism; D008325:Mammary Neoplasms, Experimental / Q000188:drug therapy*; D020714:Maximum Tolerated Dose; D051379:Mice; D018345:Mice, Knockout; D014411:Neoplastic Stem Cells / Q000145:classification
D000970:Antineoplastic Agents; D051927:CD24 Antigen; D039503:Integrin alpha6; D002945:Cisplatin